Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 06/10/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. AKRO, RYTM, ZLAB, PTCT, CYTK, RNA, KRYS, SRPT, MRUS, and ACLXShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Avidity Biosciences (RNA), Krystal Biotech (KRYS), Sarepta Therapeutics (SRPT), Merus (MRUS), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Its Competitors Akero Therapeutics Rhythm Pharmaceuticals Zai Lab PTC Therapeutics Cytokinetics Avidity Biosciences Krystal Biotech Sarepta Therapeutics Merus Arcellx Akero Therapeutics (NASDAQ:AKRO) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership. Does the MarketBeat Community favor AKRO or CALT? Akero Therapeutics received 92 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 65.75% of users gave Akero Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformAkero TherapeuticsOutperform Votes11965.75% Underperform Votes6234.25% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Which has more volatility & risk, AKRO or CALT? Akero Therapeutics has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Do insiders & institutionals have more ownership in AKRO or CALT? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is AKRO or CALT more profitable? Akero Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Akero Therapeutics' return on equity of -32.46% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -32.46% -29.83% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has preferable valuation and earnings, AKRO or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$151.76M-$1.95-27.16Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Do analysts recommend AKRO or CALT? Akero Therapeutics presently has a consensus target price of $82.50, indicating a potential upside of 55.78%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Akero Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer AKRO or CALT? In the previous week, Akero Therapeutics had 13 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 13 mentions for Akero Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Akero Therapeutics' average media sentiment score of 0.96 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Akero Therapeutics Positive Calliditas Therapeutics AB (publ) Neutral SummaryAkero Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 17 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-21.628.7827.1420.06Price / Sales0.74255.49419.32157.08Price / CashN/A65.8538.2534.64Price / Book37.746.557.064.70Net Income-$43.96M$143.93M$3.23B$247.88M7 Day PerformanceN/A3.84%2.83%2.63%1 Month PerformanceN/A11.20%9.02%6.36%1 Year Performance2.07%4.18%31.36%14.05% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AKROAkero Therapeutics3.6396 of 5 stars$54.71+0.8%$82.50+50.8%+126.0%$4.36BN/A-14.5930Insider TradeOptions VolumeHigh Trading VolumeRYTMRhythm Pharmaceuticals4.1941 of 5 stars$66.72-2.0%$76.62+14.8%+61.6%$4.24B$136.86M-15.41140Insider TradeZLABZai Lab1.4841 of 5 stars$37.87-0.6%$47.37+25.1%+106.6%$4.18B$418.33M-13.671,950Positive NewsAnalyst RevisionPTCTPTC Therapeutics4.3445 of 5 stars$51.69-0.8%$63.75+23.3%+34.8%$4.10B$1.77B-8.701,410Analyst RevisionCYTKCytokinetics4.4251 of 5 stars$33.13+2.6%$70.92+114.1%-37.9%$3.96B$19.22M-6.16250Trending NewsAnalyst ForecastAnalyst RevisionRNAAvidity Biosciences2.1688 of 5 stars$32.66-9.9%$67.62+107.0%+10.7%$3.94B$8.93M-11.34190Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeKRYSKrystal Biotech4.689 of 5 stars$136.08-0.6%$211.13+55.1%-21.3%$3.93B$333.45M45.51210Positive NewsAnalyst RevisionSRPTSarepta Therapeutics4.8283 of 5 stars$39.71-7.7%$122.61+208.8%-68.8%$3.90B$2.23B31.77840Positive NewsHigh Trading VolumeMRUSMerus3.1141 of 5 stars$54.91-2.3%$85.83+56.3%-3.6%$3.80B$54.73M-13.9037ACLXArcellx2.8152 of 5 stars$66.86-1.8%$111.33+66.5%+22.5%$3.75B$76.81M-94.1780Insider TradeAnalyst Revision Related Companies and Tools Related Companies Akero Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Zai Lab Alternatives PTC Therapeutics Alternatives Cytokinetics Alternatives Avidity Biosciences Alternatives Krystal Biotech Alternatives Sarepta Therapeutics Alternatives Merus Alternatives Arcellx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CALT Stock Free CALT Stock Alerts